Viramune Labeling Revision Warns Of Hepatic Failure In High-Risk Population
This article was originally published in The Pink Sheet Daily
Executive Summary
High-risk women taking the HIV agent should be closely monitored for hepatotoxicity during the first 18 weeks of treatment, a "Dear Doctor" letter states.